Search

everythinglearnresearchcommunity

for

Search:↓

Krill oil may help reduce prostate enlargement and growth.

Tofacitinib helps hair regrow in some kids with severe alopecia areata, but more research is needed on long-term effects.

Apremilast improved symptoms in patients with severe skin conditions.

Baricitinib is generally safe for long-term use in treating severe alopecia areata.

Longer immunotherapy treatment may improve outcomes for Merkel cell carcinoma patients.

Combining excimer lamp and tofacitinib gel may help treat hair loss in children.

New treatments for hair loss show promise, but more research is needed to confirm their safety and effectiveness.

PF-05314882 selectively activates androgen receptors without much effect on prostate and may help in prostate cancer treatment and hair loss prevention.

Tofacitinib may effectively treat hair loss and improve symptoms in autoimmune conditions like alopecia areata and Sjögren's syndrome, but long-term treatment might be necessary.

BMPR1a-ECD reduces wrinkles much more effectively than retinoic acid.

Using CDK inhibitors on rats showed a reduction in chemotherapy-caused hair loss, but later experiments could not repeat these results.

Tofacitinib nanoparticles can safely and effectively treat alopecia areata by targeting hair follicles.

Dutasteride showed some prevention of prostate issues but also had limitations, especially with high-grade tumors.

Long-term use of 5α-reductase inhibitors may improve survival in men with kidney cancer.

Baricitinib treatment for alopecia universalis can cause hair regrowth with unexpected whitening.

New drugs targeting the JAK-STAT pathway show promise for treating inflammatory skin diseases.

A man with severe hair loss saw hair and nail improvement after 10 months on tofacitinib without side effects.

Modern skin cancer treatments can cause skin side effects and hair loss, affecting patients' quality of life.

A new compound, 3a, effectively fights prostate cancer better than finasteride.

ARQ-234, a protein designed to treat atopic dermatitis, shows increased effectiveness in early testing.

Two new enzymes, PAD-R11 and PAD-R4, were cloned and showed activity, with PAD-R11 resembling epidermal enzymes.

Janus kinase inhibitors show promise in treating alopecia areata but need more safety research.

PI3Kδ inhibition may effectively treat cutaneous chronic graft-versus-host disease.

Puerariae Radix extract may help hair growth by increasing cell activity.

Tofacitinib may slow hair loss in scarring alopecias but is unlikely to regrow significant hair.

Antizyme slows skin tumor growth by reducing cell growth in mice.

Taxane chemotherapy can cause skin, hair, and nail side effects, which are often under-reported and can affect patient quality of life.

Matriptase is crucial for skin, hair, and immune cell health, and its imbalance can lead to cancer.

Oral tofacitinib may be an effective and tolerable treatment for some people with severe alopecia areata.

Baricitinib may cause low blood sugar in some patients, so careful monitoring is needed.